Loading
Overweight Or Obesity / TERN-601 / Matching Placebo · Phase 2 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed Phase 2a randomized, placebo-controlled trial of the oral GLP-1 receptor agonist TERN-601 in adults with overweight or obesity. No efficacy or safety results have been posted in this registry record; the study's contribution to the evidence base cannot yet be assessed.
Phase 2, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Overweight or Obesity; age from 18 Years; to 75 Years. Intervention: TERN-601 250 mg; TERN-601 500 mg (slow titration); TERN-601 500 mg; TERN-601 750 mg. Compared with: Matching Placebo — Placebo Comparator. n = 167. 17 sites: United States.
This is a completed Phase 2a randomized, placebo-controlled trial of the oral GLP-1 receptor agonist TERN-601 in adults with overweight or obesity. No efficacy or safety results have been posted in this registry record; the study's contribution to the evidence base cannot yet be assessed.
Efficacy, safety, and tolerability findings are not yet available in this source.
The source did not state who this applies to in practice.
Phase 2a trial with completed enrollment but no results posted in registry; early-stage efficacy and safety data pending peer-reviewed publication.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06854952). This is a study registration, not published results. Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 167 participants (ACTUAL). Conditions: Overweight or Obesity. Interventions: DRUG: TERN-601; OTHER: Matching Placebo. Primary outcome measures: Percent Change in Body Weight , 12 weeks. Brief summary: This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.